Newsfeeds - Spark Newswire

2 minute read

Looking Into Alnylam Pharmaceuticals’s Recent Short Interest

Today, 5:47 AM

Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all regular shares that are available for trading.

ALNY

1 minute read

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $291

By Benzinga Newsdesk

Today, 5:47 AM

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $310 to $291.

ALNY

1 minute read

EF Hutton Reiterates Buy on Alnylam Pharmaceuticals, Maintains $304 Price Target

By Benzinga Newsdesk

Today, 5:47 AM

EF Hutton analyst Michael King reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $304 price target.

ALNY

1 minute read

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $240 Price Target

By Benzinga Newsdesk

Today, 5:47 AM

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $240 price target.

ALNY

17 minute read

Earnings

Earnings Scheduled For February 23, 2023

By Benzinga Insights

Today, 5:47 AM

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

AAOI

1 minute read

SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Lowers Price Target to $143

By Benzinga Newsdesk

Today, 5:47 AM

SVB Leerink analyst Mani Foroohar maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and lowers the price target from $144 to $143.

ALNY

1 minute read

Piper Sandler Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $253

By Benzinga Newsdesk

Today, 5:47 AM

Piper Sandler analyst Edward Tenthoff maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $226 to $253.

ALNY

1 minute read

SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $145

By Benzinga Newsdesk

Today, 5:47 AM

SVB Leerink analyst Mani Foroohar maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and raises the price target from $142 to $145.

ALNY